An In-depth Analysis of Novavax’s New Protein-based Covid Vaccine

The Food and Drug Administration recently granted emergency use authorization for Novavax’s updated protein-based Covid vaccine for individuals aged 12 and above. This move opens up the competition between Novavax’s vaccine and the existing jabs from Pfizer and Moderna for the upcoming fall and winter season.

Novavax’s vaccine is designed to target the omicron subvariant JN.1, which has been spreading rapidly in the United States since the beginning of the year. Even though JN.1 accounts for only 0.2% of cases nationwide, the CDC’s data indicates its presence. Despite the challenges of updating protein-based vaccines quickly for new strains, Novavax assures that its vaccine offers protection against related variants such as KP.2.3, KP.3, KP.3.1.1, and LB.1.

Novavax plans to make its updated vaccine widely available in thousands of locations across the US, including retail stores, independent pharmacies, and regional grocery stores. The company’s CEO, John Jacobs, emphasized the effectiveness of their vaccine against the JN.1 lineage viruses. The positive news led to an increase in Novavax’s stock by over 8% following the FDA’s authorization.

In contrast to Pfizer and Moderna’s mRNA shots, Novavax’s protein-based vaccine offers an alternative option for individuals who may be hesitant about the newer technology. While mRNA vaccines teach cells to produce specific proteins to trigger an immune response, Novavax’s vaccine relies on established protein-based technology that has been used in other vaccinations for decades, such as hepatitis B and shingles.

As the FDA’s recent approvals of Covid vaccines from various manufacturers provide more options for the public, Novavax’s entry into the market as a protein-based alternative presents a valuable choice for those who prefer a different approach to vaccination. The decision to authorize Novavax’s vaccine for emergency use showcases the ongoing efforts to combat the pandemic and protect individuals against evolving variants. The upcoming fall and winter seasons will determine the uptake of new Covid shots, and it remains to be seen how Novavax’s vaccine will fare in the competitive landscape alongside Pfizer and Moderna.